- Trials with a EudraCT protocol (79)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
79 result(s) found for: Protein dimer.
Displaying page 1 of 4.
EudraCT Number: 2019-003959-11 | Sponsor Protocol Number: 1703001 | Start Date*: 2020-05-25 |
Sponsor Name:Vestre Viken Trust | ||
Full Title: MUscle Side-Effects of atorvastatin in coronary patients (MUSE) follow-up study | ||
Medical condition: Coronary heart disease patients With perceived statin Associated muscle symptoms or statin discontinuaton due to muscle symptoms | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001827-15 | Sponsor Protocol Number: CORTIVID | Start Date*: 2020-04-30 |
Sponsor Name:NAVARRABIOMED - FUNDACIÓN MIGUEL SERVET | ||
Full Title: EARLY TREATMENT OF PNEUMONIA COVID-19 WITH GLUCOCORTICOIDS. RANDOMIZED CONTROLLED CLINICAL TRIAL | ||
Medical condition: CoVid-19 pneumonia in early inflammatory phase (stage II). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001437-12 | Sponsor Protocol Number: COVID-19_ASS | Start Date*: 2020-04-09 | |||||||||||
Sponsor Name:Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR) | |||||||||||||
Full Title: Random, controlled, open, one-site clinical trial in adult patients with COVID-19 severe pneumonia treated with immunomodulatory drugs | |||||||||||||
Medical condition: Severe COVID-19 pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001511-25 | Sponsor Protocol Number: IMIB-COLVID-2020-03 | Start Date*: 2020-04-14 |
Sponsor Name:FFIS | ||
Full Title: Randomized open-blind controlled trial to study the benefit of Colchicine in Patients with COVID-19 | ||
Medical condition: COVID19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001708-41 | Sponsor Protocol Number: X-COVID19 | Start Date*: 2020-04-24 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA AO OSPEDALE NIGUARDA CA' GRANDA | |||||||||||||
Full Title: Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: comparison of 40 mg o.d. versus 40 mg b.i.d. A randomized Clinical Trial | |||||||||||||
Medical condition: SARS-CoV-2 Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001319-71 | Sponsor Protocol Number: F1K-MC-EVBQ | Start Date*: 2004-08-13 |
Sponsor Name:Lilly S.A. | ||
Full Title: A Phase IIIb Study to Determine Efficacy and Safety of Extended Drotrecogin Alfa (Activated) Therapy in Patients With Persistent Requirement for Vasopressor Support After 96-Hour Infusion With Comm... | ||
Medical condition: in severe sepsis patients with persistent vasopressordependent hypotension | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-001442-19 | Sponsor Protocol Number: IIBSP-COV-2020-23 | Start Date*: 2020-04-02 |
Sponsor Name:INSTITUT DE RECERCA H. SANTA CREU I SANT PAU | ||
Full Title: Pilot, randomized, multicenter, open-label clinical trial of combined use of hydroxychloroquine, azithromycin, and tocilizumab for the treatment of SARS-CoV-2 infection (COVID-19) | ||
Medical condition: COVID19 | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002476-13 | Sponsor Protocol Number: 20HH5958 | Start Date*: 2020-07-24 | ||||||||||||||||||||||||||
Sponsor Name:Imperial College London | ||||||||||||||||||||||||||||
Full Title: A study to assess the safety and efficacy of Clazakizumab in patients with COVID-19 and kidney disease. | ||||||||||||||||||||||||||||
Medical condition: Patients with kidney disease who are hospitalised with COVID-19 infection with pulmonary involvement (i.e. consistent chest imaging abnormalities) and clinical deterioration (i.e increasing oxygen ... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000199-41 | Sponsor Protocol Number: GESIDA10918 | Start Date*: 2019-07-10 | |||||||||||
Sponsor Name:Fundación SEIMC-GESIDA | |||||||||||||
Full Title: A phase IV, multicenter, open and randomized study to evaluate the impact of the change of antiretroviral treatment from dual therapy to triple therapy on inflammation in patients with type 1 HIV i... | |||||||||||||
Medical condition: HIV | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004776-56 | Sponsor Protocol Number: AT1-2017 | Start Date*: 2019-03-06 |
Sponsor Name:Arctic Therapeutics ehf | ||
Full Title: Phase IIa Biomarker Study to Evaluate the Efficacy, Safety and Tolerability of AT-1 in Patients with Hereditary Cystatin C Amyloid Angiopathy (HCCAA) - the AT1-HCCAA study | ||
Medical condition: Hereditary Cystatin C Amyloid Angiopathy (HCCAA) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IS (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2021-002744-74 | Sponsor Protocol Number: F3-IROzono-COVID-19 | Start Date*: 2022-06-23 | |||||||||||
Sponsor Name:Sociedad Española de Ozonoterapia - SEOT [...] | |||||||||||||
Full Title: Effect of rectal ozone therapy on the clinical progress of hospitalized patients with mild-moderate covid19 infection: A triple- blind, randomized controlled trial. | |||||||||||||
Medical condition: COVID-19 infection requiring hospitalization | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001779-31 | Sponsor Protocol Number: FONDAPARINUX | Start Date*: 2008-05-09 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI | |||||||||||||
Full Title: Markers of hypercoagulability and risk of death and rehospitalization in heart failure patients: a pilot study on the effects of Fondaparinux | |||||||||||||
Medical condition: heart failure patients (III-IV NYHA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004578-40 | Sponsor Protocol Number: SSAT066 | Start Date*: 2015-01-26 |
Sponsor Name:St Stephen's AIDS Trust | ||
Full Title: A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal ... | ||
Medical condition: HIV | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-000795-19 | Sponsor Protocol Number: HIPRA-HH-10 | Start Date*: 2022-03-10 | |||||||||||
Sponsor Name:HIPRA SCIENTIFIC | |||||||||||||
Full Title: A PHASE IIB, DOUBLE-BLIND, RANDOMIZED, ACTIVE CONTROLLED, MULTI-CENTER, NON-INFERIORITY TRIAL TO ASSESS IMMUNOGENICITY AND SAFETY OF A BOOSTER VACCINATION WITH A RECOMBINANT PROTEIN RBD FUSION DIME... | |||||||||||||
Medical condition: SARS-COV-2 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001929-31 | Sponsor Protocol Number: ESCORPIO | Start Date*: 2020-06-16 |
Sponsor Name:Fundación Investigación Biomédica Hospital Ramón y Cajal | ||
Full Title: Controlled, randomized, non-blind trial on the usefulness of pioglitazone treatment in patients with type 2 diabetes mellitus and COVID-19. | ||
Medical condition: COVID-19 in patients with diabetes mellitus type 2 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001808-42 | Sponsor Protocol Number: PHM-2020-001 | Start Date*: 2020-06-17 | |||||||||||
Sponsor Name:Pharmamel S.L. | |||||||||||||
Full Title: PHASE II CLINICAL TRIAL, SINGLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED TO EXPLORE THE EFFECTIVENESS AND SAFETY OF MELATONIN I.V. IN PATIENTS WITH COVID-19 ENTERED INTO THE ICU (MELCOVID STUDY) | |||||||||||||
Medical condition: COVID-19 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002722-36 | Sponsor Protocol Number: RAGTIME | Start Date*: 2017-03-29 | |||||||||||
Sponsor Name:FUNDACIÓ LLUITA CONTRA LA SIDA | |||||||||||||
Full Title: Randomized, double-blind, placebo-controlled clinical trial to evaluate the effect of Raltegravir intensification (1.200 mg QD) on the gut microbiota of chronically HIV-1 infected subject over time... | |||||||||||||
Medical condition: HIV-1 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001172-15 | Sponsor Protocol Number: APN01-01-COVID19 | Start Date*: 2020-04-08 |
Sponsor Name:APEIRON Biologics AG | ||
Full Title: Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19 | ||
Medical condition: Severe COVID-19 POSITIVE hospitalized male or female, between 18 and ≤ 80 years of age | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) DK (Completed) AT (Completed) GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2020-001937-11 | Sponsor Protocol Number: 132333 | Start Date*: 2020-04-30 |
Sponsor Name:University College London | ||
Full Title: A single-site, randomised, controlled, parallel design, open-label investigation of an approved nebulised recombinant human DNase enzyme (dornase alfa) to reduce hyperinflammation in hospitalised p... | ||
Medical condition: Respiratory illness caused by Covid-19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2011-004834-32 | Sponsor Protocol Number: PROTEINA-C | Start Date*: 2012-06-08 | |||||||||||
Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR | |||||||||||||
Full Title: Administration of concentrated Protein C in patients with severe sepsis and contraindications to activated protein C. A monocentric, randomised placebo-controlled study. | |||||||||||||
Medical condition: patients affected by severe sepsis admitted to intensive care | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
